Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib

Journal of Drugs in Dermatology

Volumn 10, Issue 3, 2011, Pages 308-310

  Lynch, Michael C ^a   Straub, Renee ^b   Adams, David R ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; LOPERAMIDE; SORAFENIB;

AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER RECURRENCE; CASE REPORT; DIARRHEA; DRUG TOLERABILITY; ELECTRODESSICATION AND CURETTAGE; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOACANTHOMA; LIVER NEOPLASMS; MALE; PYRIDINES; SKIN NEOPLASMS;

EID: 80053010052     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
2. Chaparro M, Moreno LG, Trapero-Marugán M, et al. Review article: Pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther. 2008;28:1269-1277.
3. Widakowich C, De Castro G, De Azambuja E, et al. Review: Side effects of approved molecular targeted therapies in solid cancers. The Oncologist. 2007;12:1443-1455.
4. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299-305.
5. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):59-61.
6. Diamantis ML, Chon SY. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol. 2010;9:169-171.
7. Smith KJ, Haley H, Hamza S, et al. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35:1766-1770.
8. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56:171-172.
9. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: Practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562-568.
10. Marquez CB, Smithberger EE, Bair SM, et al. Multiple keratoacanthomas arising in the setting of sorafenib therapy: Novel chemoprophylaxis with bexarotene. Cancer Control. 2009;16:66-69.
11. Street ML, White JW Jr, Gibson LE. Multiple keratoacanthomas treated with oral retinoids. J Am Acad Dermatol. 1990;23:862-866. (Pubitemid 20366095)